Oramed Pharmaceuticals (ORMP) Total Debt (2011 - 2024)

Oramed Pharmaceuticals' (ORMP) quarterly Total Debt came in at $32.0 million in Q1 2024, down 37.2% on a QoQ basis from $51.0 million in Q4 2023.

Oramed Pharmaceuticals (ORMP) Total Debt (2011 - 2024) Analysis & Trends

Oramed Pharmaceuticals (ORMP) has 11 years of Total Debt data on file, last reported at $32.0 million in Q1 2024.

Quarterly Total Debt changed N/A year-over-year to $32.0 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $32.0 million (changed N/A YoY) and the FY2023 annual result came in at $51.0 million, changed N/A from the prior year.
Total Debt retreated to $32.0 million in Q1 2024, from $51.0 million in the prior quarter.
In the past five years, Total Debt ranged from a high of $75.4 million in Q3 2023 to a low of $43000.0 in Q1 2020.
A 4-year average of $17.6 million and a median of $90000.0 in 2020 frame the typical range for Total Debt.
Annual changes were most pronounced in 2020 — Total Debt decreased 21.82% — and 2021, when it surged 102.33%.
Tracing ORMP's Total Debt over 4 years: stood at $93000.0 in 2020, then sank by 37.63% to $58000.0 in 2021, then surged by 87853.45% to $51.0 million in 2023, then sank by 37.2% to $32.0 million in 2024.
The last three Total Debt figures came in at $32.0 million (Q1 2024), $51.0 million (Q4 2023), and $75.4 million (Q3 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	770.36 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	9.34 Bn
10	Oramed Pharmaceuticals	197.61 Mn	197.61 Mn	-	-

Download Data